_20240730163304_original_image_14.webp)
Patients treated with Nimotuzumab alongside concurrent radiotherapy and cisplatin showed a 10-year overall survival rate of 33.5 per cent, compared to 22.5 per cent for those who received only radiotherapy and cisplatin
Read More
This research will extend to cancer subtypes such as Langerhans Cell Histiocytosis (LCH), an immune cell disorder predominantly affecting children aged 0 to 15 years
Read More
